CTOs on the Move


 
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vical.com
  • 10390 Pacific Center Ct
    San Diego, CA USA 92121
  • Phone: 858.646.1100

Executives

Name Title Contact Details

Similar Companies

JOM Pharmaceutical Services

JOM Pharmaceutical Services is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZestDentalSolutions

ZEST Dental Solutions has been manufacturing overdenture implant attachment systems as a global leader and being one of the top dental implant manufacturers for over forty years.

Advarra

Advarra Integrated Solutions enable the safe, ethical, compliant, and efficient development of life-changing therapies.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.